The continuation vehicle secured approximately $2.3 billion in commitments and was led by CVC Secondary Partners.

Cerberus Capital Management, L.P. (together with its affiliates, "Cerberus"), a global alternative investment firm, today announced the closing of a single-asset continuation vehicle for Subsea ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

The Brown County Quality of Life Board (QOLAB) began in early 2025 as an informal gathering of diverse community leaders at ...

Harshita Kejriwal, the daughter of Arvind Kejriwal and Sunita Kejriwal, scored an impressive 98 percent in her Class 10th ...

Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global ...

ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for ...

Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. In this phase 3, double-blind, randomized, ...

Edge, a new digital assets financial services firm, founded by veterans of traditional finance and crypto markets, has emerged from stealth as it prepares ...

A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.